肺癌是最常见的肿瘤疾病,其中大约85%的肺癌患者被诊断为非小细胞肺癌(NSCLC),但经过术后的放化疗效果都不太理想,目前免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现给NSCLC的治疗带来革命性的治疗方案。本文将重点对新...肺癌是最常见的肿瘤疾病,其中大约85%的肺癌患者被诊断为非小细胞肺癌(NSCLC),但经过术后的放化疗效果都不太理想,目前免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现给NSCLC的治疗带来革命性的治疗方案。本文将重点对新辅助免疫疗法联合化疗治疗NSCLC的机制、临床研究,及新辅助治疗后手术效果等方面进行综述。Lung cancer is the most common tumor disease, in which about 85% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC), but after postoperative radiotherapy are less effective, the current emergence of immune checkpoint inhibitors (ICIs) has brought revolutionary therapeutic options to the treatment of NSCLC. In this paper, we will focus on the review of the mechanism, clinical research, and surgical outcome after neoadjuvant immunotherapy combined with chemotherapy for NSCLC.展开更多
文摘肺癌是最常见的肿瘤疾病,其中大约85%的肺癌患者被诊断为非小细胞肺癌(NSCLC),但经过术后的放化疗效果都不太理想,目前免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现给NSCLC的治疗带来革命性的治疗方案。本文将重点对新辅助免疫疗法联合化疗治疗NSCLC的机制、临床研究,及新辅助治疗后手术效果等方面进行综述。Lung cancer is the most common tumor disease, in which about 85% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC), but after postoperative radiotherapy are less effective, the current emergence of immune checkpoint inhibitors (ICIs) has brought revolutionary therapeutic options to the treatment of NSCLC. In this paper, we will focus on the review of the mechanism, clinical research, and surgical outcome after neoadjuvant immunotherapy combined with chemotherapy for NSCLC.
